-
1 Comment
Jiangsu Hengrui Medicine Co., Ltd is currently in a long term downtrend where the price is trading 20.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
Jiangsu Hengrui Medicine Co., Ltd's total revenue rose by 17.1% to $8B since the same quarter in the previous year.
Its net income has increased by 20.7% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 61.2% to $382M since the same quarter in the previous year.
Based on the above factors, Jiangsu Hengrui Medicine Co., Ltd gets an overall score of 2/5.
| Industry | Drug Manufacturers-General |
|---|---|
| Sector | Healthcare |
| ISIN | CNE0000014W7 |
| CurrencyCode | CNY |
| Exchange | SHG |
| Beta | 0.24 |
|---|---|
| Dividend Yield | 0.4% |
| Market Cap | 304B |
| PE Ratio | 86.76 |
| Target Price | 51.6 |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600276.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
